When the male group was analysed, TERC rs12696304 was found to be associated with a decreased odds of MS occurrence in males in the codominant, dominant, and additive models (5.5-fold (OR: 0.182, (95% CI: 0.037–0.894), p = 0.036), 2-fold (OR = 0.507, (95% CI: 0.284–0.903), p = 0.021), and 1.9-fold (OR: 0.515, (95% CI: 0.314–0.845), p = 0.009), respectively). The gene discussed is TERC; the disease is myeloid sarcoma.